{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:53:45Z","timestamp":1759496025786,"version":"3.41.2"},"reference-count":36,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND AND OBJECTIVES<\/jats:title>\n                  <jats:p>On June 4, 2021, Italy launched the coronavirus disease 2019 (COVID-19) vaccination of adolescents to slow down the COVID-19 spread. Although clinical trials have evaluated messenger ribonucleic acid (mRNA) vaccine effectiveness in adolescents, there is limited literature on its real-world effectiveness. Accordingly, this study aimed to estimate the effectiveness of mRNA COVID-19 vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and mild or severe COVID-19 in a cohort of Sicilian adolescents within a 6 month observation period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>A retrospective cohort study was conducted with adolescents aged 12 to 18 years, residents of Sicily, who were followed from July 15 to December 31, 2021. SARS-CoV-2 infections, mild and severe COVID-19, and COVID-19-related intubation or deaths during the study period were compared between subjects vaccinated with 2 doses of mRNA vaccines and unvaccinated individuals. The Cox regression analysis, adjusted for age and sex, was performed to compare the 2 groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Overall, the study included a total at-risk population of 274\u2009782 adolescents with 61.4% of them having completed the vaccination cycle by the end of the study. Unvaccinated subjects had higher incidence rates of SARS-CoV-2 (1043 \u00d7 10\u2009000 vs 158.7 \u00d7 10\u2009000 subjects), mild COVID-19 (27.7 \u00d7 10\u2009000 vs 1.8\u2009\u00d7\u200910\u2009000 subjects) and severe COVID-19 (1.41 \u00d7 10\u2009000 vs 0 subjects) compared with the vaccinated population. The estimated adjusted vaccine effectiveness against SARS-CoV-2 infection was 71.2%, reaching 92.1% and 97.9% against mild and severe COVID-19, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>This study provides rigorous evidence of mRNA COVID-19 vaccines\u2019 effectiveness in protecting adolescents from both SARS-CoV-2 infection and COVID-19.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2022-057394","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T04:04:25Z","timestamp":1660104265000},"source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness of mRNA COVID-19 Vaccines in Adolescents Over 6 Months"],"prefix":"10.1542","volume":"150","author":[{"given":"Emanuele","family":"Amodio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Genovese","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Mazzeo","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Martino","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Restivo","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Vella","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Calamusa","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Vitale","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"2023110816573660700_B1","unstructured":"World Health Organization (WHO)\n          . COVID-19 dashboard. Available at: https:\/\/covid19.who.int. Accessed July 6, 2022"},{"issue":"2","key":"2023110816573660700_B2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/cells10020206","article-title":"COVID-19: characteristics and therapeutics","volume":"10","author":"Chilamakuri","year":"2021","journal-title":"Cells"},{"issue":"6","key":"2023110816573660700_B3","doi-asserted-by":"crossref","first-page":"2000562","DOI":"10.1183\/13993003.00562-2020","article-title":"Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China","volume":"55","author":"Liang","year":"2020","journal-title":"Eur Respir J"},{"issue":"6","key":"2023110816573660700_B4","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.3390\/jcm9061733","article-title":"A cohort of patients with COVID-19 in a major teaching hospital in Europe","volume":"9","author":"Borobia","year":"2020","journal-title":"J Clin Med"},{"issue":"5","key":"2023110816573660700_B5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/jgs.16407","article-title":"Novel coronavirus (COVID-19) epidemic: what are the risks for older patients?","volume":"68","author":"Garnier-Crussard","year":"2020","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"2023110816573660700_B6","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.18632\/aging.103344","article-title":"Why does COVID-19 disproportionately affect older people?","volume":"12","author":"Mueller","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"23","key":"2023110816573660700_B7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.15585\/mmwr.mm7023e1","article-title":"Hospitalization of adolescents aged 12-17 years with laboratory-confirmed COVID-19 - COVID-NET, 14 States, March 1, 2020-April 24, 2021","volume":"70","author":"Havers","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023110816573660700_B8","doi-asserted-by":"crossref","first-page":"649358","DOI":"10.3389\/fped.2021.649358","article-title":"Epidemiology, clinical features and prognostic factors of pediatric SARS-CoV-2 infection: results from an Italian multicenter study","volume":"9","author":"Garazzino","year":"2021","journal-title":"Front Pediatr"},{"key":"2023110816573660700_B9","unstructured":"Centers for Disease Control and Prevention (CDC) Health Advisory\n          . Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). Available at: https:\/\/emergency.cdc.gov\/han\/2020\/han00432.asp. Accessed May 3, 2022"},{"issue":"11","key":"2023110816573660700_B10","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1001\/jama.2021.2091","article-title":"Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19","volume":"325","author":"Feldstein","year":"2021","journal-title":"JAMA"},{"key":"2023110816573660700_B11","unstructured":"European Centre for Disease Prevention and Control (ECDC)\n          . COVID-19 vaccine tracker. Available at: https:\/\/vaccinetracker.ecdc.europa.eu\/public\/extensions\/covid-19\/vaccine-tracker.html#uptake-tab. Accessed July 6, 2022"},{"key":"2023110816573660700_B12","unstructured":"Centre for Disease Control and Prevention (CDC)\n          . COVID data tracker. Available at: https:\/\/covid.cdc.gov\/covid-data-tracker\/#vaccinations_vacc-people-additional-dose-totalpop. Accessed July 6, 2022"},{"issue":"3","key":"2023110816573660700_B13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"2023110816573660700_B14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/vaccines9030189","article-title":"Who should get COVID-19 vaccine first? A survey to evaluate hospital workers' opinion","volume":"9","author":"Crax\u00ec","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2023110816573660700_B15","unstructured":"Italian Medicines Agency (AIFA)\n          . Comirnaty \u2013 BioNTech\/Pfizer. Available at: https:\/\/www.aifa.gov.it\/en\/comirnaty. Accessed May 3, 2022"},{"key":"2023110816573660700_B16","unstructured":"Italian Medicines Agency (AIFA)\n          . Spikevax \u2013 vaccine Moderna mRNA-1273. Available at: https:\/\/www.aifa.gov.it\/en\/moderna. Accessed May 3, 2022"},{"key":"2023110816573660700_B17","unstructured":"Istituto Superiore di Sanit\u00e0 COVID-19 Task Force\n          . Epidemia COVID-19: aggiornamento nazionale 15 settembre 2021 \u2013 ore 12:00. Available at: https:\/\/www.epicentro.iss.it\/coronavirus\/bollettino\/Bollettino-sorveglianza-integrata-COVID-19_15-settembre-2021.pdf. Accessed May 3, 2022"},{"key":"2023110816573660700_B18","unstructured":"Istituto Superiore di Sanit\u00e0 COVID-19 Task Force\n          . Epidemia COVID-19: aggiornamento nazionale 5 gennaio 2022 \u2013 ore 12:00. Available at: https:\/\/www.epicentro.iss.it\/coronavirus\/bollettino\/Bollettino-sorveglianza-integrata-COVID-19_5-gennaio-2022.pdf. Accessed May 3, 2022"},{"key":"2023110816573660700_B19","unstructured":"Italian Minister of Health\n          . Coronavirus, new record of almost 3,000 recoveries in one day. Available at: https:\/\/www.salute.gov.it\/portale\/nuovocoronavirus\/dettaglioNotizieNuovoCoronavirus.jsp?lingua=english&menu=notizie&p=dalministero&id=4570. Accessed May 3, 2022"},{"volume-title":"RStudio: Integrated Development for R. RStudio","year":"2020","author":"RStudio Team","key":"2023110816573660700_B20"},{"issue":"39","key":"2023110816573660700_B21","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.15585\/mmwr.mm6939e2","article-title":"COVID-19 trends among school-aged children - United States, March 1-September 19, 2020","volume":"69","author":"Leeb","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"2023110816573660700_B22","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1093\/cid\/ciaa556","article-title":"SARS-CoV-2 (COVID-19): what do we know about children? A systematic review","volume":"71","author":"Mehta","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"10287","key":"2023110816573660700_B23","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. [published correction appears in Lancet. 2021 Jul 17;398(10296): 212]","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"issue":"5152","key":"2023110816573660700_B24","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.15585\/mmwr.mm705152a2","article-title":"Interim estimate of vaccine effectiveness of BNT162b2 (Pfizer-BioNTech) vaccine in preventing SARS-CoV-2 infection among adolescents aged 12-17 Years \u2013 Arizona, July-December 2021","volume":"70","author":"Lutrick","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"2023110816573660700_B25","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.3201\/eid2711.211886","article-title":"Effectiveness of BNT162b2 vaccine in adolescents during outbreak of SARS-CoV-2 Delta variant infection, Israel, 2021","volume":"27","author":"Glatman-Freedman","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"2023110816573660700_B26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3390\/vaccines10030426","article-title":"Effectiveness of mRNA COVID-19 vaccination on SARS-CoV-2 infection and COVID-19 in Sicily over an eight-month period","volume":"10","author":"Amodio","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"22","key":"2023110816573660700_B27","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1056\/NEJMc2114290","article-title":"Effectiveness of BNT162b2 vaccine against Delta variant in adolescents","volume":"385","author":"Reis","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"2023110816573660700_B28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJMoa2117995","article-title":"Effectiveness of BNT162b2 vaccine against critical Covid-19 in adolescents","volume":"386","author":"Olson","year":"2022","journal-title":"N Engl J Med"},{"issue":"20","key":"2023110816573660700_B29","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa2202826","article-title":"BNT162b2 protection against the Omicron variant in children and adolescents","volume":"386","author":"Price","year":"2022","journal-title":"N Engl J Med"},{"issue":"27","key":"2023110816573660700_B30","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"2023110816573660700_B31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/vaccines10030345","article-title":"Adverse reactions to anti-SARS-CoV-2 vaccine: a prospective cohort study based on an active surveillance system","volume":"10","author":"Amodio","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"10309","key":"2023110816573660700_B32","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"journal-title":"medRxiv","article-title":"Waning effectiveness of the BNT162b2 vaccine against infection in adolescents. [published online ahead of print January 5, 2022]","author":"Prunas","key":"2023110816573660700_B33"},{"issue":"4","key":"2023110816573660700_B34","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by Covid-19 vaccines","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"2023110816573660700_B35","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa2109522","article-title":"Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents","volume":"385","author":"Ali","year":"2021","journal-title":"N Engl J Med"},{"key":"2023110816573660700_B36","unstructured":"World Health Organization (WHO)\n          . Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19: interim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022. Available at: https:\/\/apps.who.int\/iris\/handle\/10665\/352124. Accessed May 3, 2022"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2022-057394\/1562829\/peds_2022057394.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2022-057394\/1562829\/peds_2022057394.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T16:59:08Z","timestamp":1699462748000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/150\/5\/e2022057394\/188742\/Effectiveness-of-mRNA-COVID-19-Vaccines-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,10,21]]},"published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2022-057394","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2022,10,21]]},"article-number":"e2022057394"}}